alexa Drugs|Omics Group|Health Care: Current Reviews

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Drugs

Ibrutinib is a BTK inhibitor recently approved, February 2014, for the treatment of recurrent CLL. BTK plays an important role downstream the B cell receptor signaling (BCR) and is part of the Tec family of kinases. Signaling through BCR is essential to the AKT pathway and the NF-ΚB pathway (nuclear factor kappa light-chain enhancer of activated B cells). BCR signaling is also involved in B cells cell adhesion, migration and differentiation. Ibrutinib has been evaluated as frontline in elderly patients. It was found that the toxicities associated to this agent were mild. For example 68% of patients had grade 1 diarrhea and 45% grade 2 diarrhea. New Therapeutic Advances in CLL (Ghayathri Jeyakumar)
 
  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger
 
adwords